SNPX: Neurotrope Market Cap to Earnings
Synaptogenix, Inc. (SNPX) focuses on discovering dementia therapies by studying synapse regeneration and conducting trials of Bryostatin-1. The quotes provided below are fixed at 0.00. Simultaneously, Inertia is developing anti-neurodegeneration agents, which will ensure stable demand throughout the duration of patent ownership. However, the business is currently only consuming capital, lacking operational income sources to generate profit.
Analytical breakdowns for Neurotrope (SNPX)
- market value and analyst target forecast:
- market capitalization information:
- book value of equity indicators:
- company liabilities and liquidity data:
- financial results and valuation multiples details:
SNPX - Company Net Income|Net Profit Forecast Synaptogenix, Inc.|SNPX - P/E Multiple|Market Cap to Projected Earnings Synaptogenix Inc.|SNPX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Synaptogenix, Inc.|SNPX - Operating profit before deduction of amortization|Earnings per share for the trailing year Synaptogenix|SNPX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months synaptogen.com|SNPX - Earnings per share growth in current year|Projected earnings per share growth rate for next year Synaptogenix, Inc.
Comprehensive company analysis:SNPX (synaptogen.com)
Analyzing the assets of Synaptogenix, Inc. (SNPX) requires a precise assessment of market expectations. The company's fundamental P/E multiple relates the current share price to annual net income, determining the price per unit of profit. An increase in this indicator signals investor confidence in the future success of biopharmaceutical developments. The effective implementation of ESG standards and bioethics reduces operational risks, supporting investment attractiveness. Valuation stability confirms the capital's resilience to external shocks.
Key competitors
biogen.com (BIIB) - Business Payback Period|Price to Earnings Ratio NBIX (Neurocrine Biosciences, Inc.)|RGC - Market Cap to Earnings|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACAD: Price to Earnings Multiple|Xenon Pharmaceuticals - P/E Multiple|VKTX - P/E Multiple|Supernus (SUPN) - Price to Earnings Ratio|Market Cap to Net Income CPRX (Catalyst Pharma)|Price to Earnings Ratio DNLI|HRMY (Harmony Corp) - Market Price to Net Income Ratio|Price to Earnings Ratio Biohaven Ltd. (BHVN)|AMLX - Market Cap to Earnings|P/E Multiple TRVI (Trevi Therapeutics, Inc.)|Market Cap to Net Income Ratio Praxis Precision Medicines Inc|Anavex Corp - P/E Multiple|Market Cap to Earnings CeriBell EEG|prothena.com (PRTA) - Price to Earnings Ratio|Price to Earnings Multiple ALEC|ANNX (Annexon) - P/E Multiple|Omeros Corp. (OMER) - Business Payback Period|Price to Earnings Ratio NGNE (Neurogene Corp)|AC Immune Inc - Price to Earnings Multiple|Voyager Therapeutics - Price to Earnings Ratio|Company Value to Net Income NMRA|Scilex - P/E Multiple|Business Payback Period Tevogen Bio Holdings Inc. TVGN|alphacognition.com (ACOG) - Price to Earnings Ratio|Price to Earnings Multiple CGTX|IKT (Inhibikase Therapeutics) - P/E Multiple|Price to Earnings Ratio cassavasciences.com (SAVA)|Price to Earnings Ratio ASRT (Assertio Holdings, Inc.)|Business Payback Period coyatherapeutics.com|Price to Earnings Ratio Vistagen VTGN|Business Payback Period Ovid Therapeutics Inc (OVID)|ABOS - Price to Earnings Ratio|CRVO (cervomed.com) - Price to Earnings Multiple|alteritytherapeutics.com (ATHE) - Price to Earnings Ratio|Market Cap to Net Income CLNN (Clene)|Price to Earnings Ratio PEPG|Price to Earnings Multiple JUNS (Jupiter Neurosciences, Inc.)|Price to Earnings Ratio Relmada Therapeutics (RLMD)|annovisbio.com - Price to Earnings Multiple|P/E Multiple GRCE (Grace Therapeutics)|Firefly Neuroscience, Inc. (AIFF) - Market Cap to Earnings|KLTO: Price to Earnings Ratio|NRSN - P/E Multiple|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MetaVia - Company Value to Net Income|Price to Earnings Ratio NeurAxis|Market Cap to Earnings Helius Medical Technologies Inc. HSDT|Price to Earnings Ratio Passage Bio, Inc. (PASG)|Business Payback Period bionomics.com.au|Minerva Neurosciences - Price to Earnings Ratio|athira.com (ATHA) - Market Cap to Earnings|ADXN - Price to Earnings Ratio|ALZN (Alzamend Neuro, Inc.) - Price to Earnings Multiple|CYCN: P/E Multiple|Protagenic Therapeutics, Inc. (PTIX) - P/E Multiple|Price to Earnings Ratio Pasithea Therapeutics Corp|Cortigent Medical - Market Cap to Net Income|Price to Earnings Ratio ATXI (Avenue Therapeutics, Inc.)|Market Price to Net Income Ratio BCLI|Price to Earnings Ratio Cara Therapeutics, Inc CARA|Chromocell (CHRO) - Market Cap to Earnings|Eliem - P/E Multiple|Market Cap to Net Income Ratio Intra-Cellular Therapies (ITCI)|LBPH: P/E Multiple|Market Cap to Earnings Marinus Pharmaceuticals Inc (MRNS)|Price to Earnings Ratio NKGen|Price to Earnings Multiple NRBO (NeuroBo Pharma)|P/E Multiple SAGE|Business Payback Period trevena.com|Vigil Neuroscience, Inc. - Price to Earnings Ratio|WENA: Price to Earnings Multiple|CERE: Price to Earnings Ratio
